A white "Biointelect" logo is displayed against a dark green/black background.
Search
Contact Us
  • Resources

Contemporary issues in valuing new oncology medicines: Do we need a new model?

Home › Resources › Contemporary issues in valuing new oncology medicines: Do we need a new model?

In 2019 Biointelect hosted its second annual medicines policy symposium, this report summarises the main points of the presentation discussing this topic. The main discussions being the challenges of valuation of new oncology medicines, whether oncology submissions are optimal for assessment of value, what is to be learnt from the international discussion on valuation and the perspective of the patients, the ultimate stakeholder.

Download

Related Resources

Want To Find Out More?

Are you interested in learning more about Biointelect, including our current white paper submissions and health policy related work?

Get in touch with our team to discover how we’re advancing healthcare for all and how you can harness our intellect and proven expertise in bringing innovative life science to market.

Contact Us

Eri Nishiuchi

Strategic Development and Business Effectiveness

Eri Nishiuchi holds a Bachelor of Business degree from the University of Technology Sydney. Her expertise lies in health systems analysis and client relationship management within the healthcare and life sciences sectors. She also has experience working with patient organisations.

Throughout her career, Eri has provided competitive landscape research support to pharmaceutical and biotech clients across the Asia Pacific region, achieving one of the top client retention rates in the region. Her multilingual abilities have been instrumental in fostering strong relationships with diverse stakeholders.

Eri joined Biointelect in 2024 in a strategic development and business effectiveness role, where her focus will be on conducting market analysis and improving business processes.